Lensar integrating phacoemulsification technology from Oertli Instrumente AG into adaptive cataract treatment system

News
Article

Surgeons can save space and optimise workflow efficiency in the operating room

A close-up of an eye with a laser effect hitting it. Image credit: ©Mongkolchon – stock.adobe.com

CEO of Lensar, Nick Curtis, said the company was pleased to offer Oertli's phaco technology as an option to their customers.

Image credit: ©Mongkolchon – stock.adobe.com

On Monday, Lensar Inc. announced a step forward in its plans to integrate phacoemulsification technology from Oertli Instrumente AG, a Swiss manufacturer and industry leader in phacoemulsification, into the ALLY adaptive cataract treatment system.

According to a news release, Oertli filed an 510(k) with the FDA for its Faros device, which if cleared, will bring Lensar a step closer to deliver combined femto phaco technology. Lensar noted in its news release the combined femtosecond laser and phacoemulsification system will be the first system to combine these technologies, changing the paradigm in cataract surgery.

The current ALLY system has quickly gained adoption among cataract surgeons for its advantages in efficiency and clinical results. Surgeons have the option of performing FLACS procedures in a completely sterile environment, moving from laser to phaco, saving between 8 and 10 minutes per procedure with ALLY. With the combined system surgeons will also save space in the operating room and optimise cataract surgery, all on one system.

Nick Curtis, CEO of Lensar, said the company was pleased to present the phaco technology, developed by Oertli, as an option to their customers.

“This combined system will be the first ever on the market, demonstrating our commitment to change the paradigm in cataract surgery,” he said in the company’s news release. “ALLY will offer even more ways for surgeons to optimise their workflow and improve the patient experience.”

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.